Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin and Linagliptin in Pediatric Type 2 Diabetes (DINAMO)
CTR20181877Phase 3Terminated
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of empagliflozin in type 2 diabetes mellitus (T2DM), sponsored by Boehringer Ingelheim. Started Nov 2018; status: terminated.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20181877.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20181877.